Parkinson's disease (PD) results primarily from the death of dopaminergic neurons in the
substantia nigra. Current PD medications treat symptoms; none halt or retard dopaminergic …

This article reviews and summarizes 200 years of Parkinson's disease. It comprises a relevant
history of Dr. James Parkinson's himself and what he described accurately and what he …

… and will thus not be discussed herein, but any reader interested in acquiring further
information regarding this aspect of 6-OHDA biology is encouraged to refer to Przedborski and …

Minocycline mediates neuroprotection in experimental models of neurodegeneration. It
inhibits the activity 1 , 2 , 3 , 4 , 5 , 6 of caspase-1, caspase-3, inducible form of nitric oxide …

… A prerequisite for Parkin’s actions on mitochondria may be its translocation from the
cytosol to mitochondria, as shown after a dissipation of ΔΨ m with the protonophore carbonyl …

MPTP (1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine) damages dopaminergic neurons as
seen in Parkinson disease. Here we show that after administration of MPTP to mice, there …

… PMNs and ESMNs was caused by soluble factor(s), we plated eGFP PMNs onto coverslips …
the release of soluble factor(s). This putative toxic mediator(s) seems specific to astrocytes, as …

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) damages the nigrostriatal dopaminergic
pathway as seen in Parkinson's disease (PD), a common neurodegenerative disorder with …

… χ 2 tests were used to compare proportions, and Student’s t-tests were used to compare
means in these analyses. Similar analyses were performed to compare subjects who did and …

This protocol describes our method of producing a reliable mouse model of Parkinson's
disease (PD) using the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). We …